Would you add olaparib to maintenance immunotherapy for a patient with recurrent MMR-proficient, HER2-negative serous endometrial carcinoma?
Community PollStarted
In what clinical setting do you believe PARP inhibitors have an appropriate role in patients with endometrial cancer?
68 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Gynecologic Oncology · University of Alabama at Birmingham
Answered on
I think it is reasonable to treat HER2 non-amplified USC with anti-PD-1 in addition to chemotherapy as long as they are TP53 mutated (90-95%) of tumors. This was looked at in a survival sub-analysis in RUBY. Other considerations would be bevacizumab, as there is evidence this works in TP53 mutated t...
Join for free or sign in to see the full answer